{"id":"W4399394934","doi":"10.1200/jco.2024.42.16_suppl.5020","title":"Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Alternative medicine; Prostate cancer; Pathology; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001632757,0.0006212433,0.0007855491,0.0003171273,0.0001976999,0.000605275,0.0005050123,0.0005437403,0.003018984],"category_scores_gemma":[0.001067619,0.0003010632,0.0007057609,0.0002510053,0.0003998665,0.0005262516,0.0002555341,0.001173817,0.0004342406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006800198,"about_ca_system_score_gemma":0.0006631925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004969977,"about_ca_topic_score_gemma":0.001645246,"domain_scores_codex":[0.999642,0.0001790256,0.00002025628,0.0000618398,0.00005878452,0.00003806735],"domain_scores_gemma":[0.9992632,0.0001692684,0.0002692571,0.00005247288,0.00004582535,0.0001998967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7614061,0.01649937,0.06725222,0.0007896659,0.002116373,0.0001492288,0.0002222706,0.002612082,0.0422792,0.0001758962,0.002378629,0.1041188],"study_design_scores_gemma":[0.2588458,0.4759535,0.229885,0.0001372587,0.003296275,0.000835849,0.000162277,0.008585511,0.01772852,0.000481457,0.003982617,0.0001058681],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960173,0.001360106,0.0002542475,0.0001755542,0.00002597144,0.0005150005,0.0007544764,0.00003095872,0.000866322],"genre_scores_gemma":[0.997489,0.0003025332,0.0003565349,0.0001745544,0.00003722619,0.0003238046,0.0007302528,0.00000698566,0.0005790661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003018984,"threshold_uncertainty_score":0.01009947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1426842478758812,"score_gpt":0.5026659190322387,"score_spread":0.3599816711563575,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}